|Bid||50.66 x 3000|
|Ask||50.97 x 3100|
|Day's Range||50.61 - 51.28|
|52 Week Range||46.48 - 64.94|
|Beta (5Y Monthly)||0.19|
|PE Ratio (TTM)||41.73|
|Forward Dividend & Yield||1.40 (2.81%)|
|Ex-Dividend Date||Feb 25, 2021|
|1y Target Est||63.60|
Blood clot concerns lack context, experts say, putting pressure on federal agencies to unpause J&J vaccinations.
Health professionals say the Johnson & Johnson and AstraZeneca sagas, reports of vaccinated people catching the virus, and other risks are built into the entire process.
The risk of contracting blood clots is much higher for Covid-19 patients than from vaccines, according to a study released on Thursday. The rare blood clotting known as cerebral venous thrombosis, or CVT, occurred at a rate of 39 per million Covid 19 patients, according to researchers at the University of Oxford, the same university that helped develop the AstraZeneca vaccine. Firstly, Covid-19 markedly increases the risk of CVT, adding to the list of blood clotting problems this infection causes.